Animas Corp.
This article was originally published in Start Up
Executive Summary
Animas's Corp. ambition is the development of an insulin infusion pump and an implantable optical glucose sensor for insulin-dependent diabetes.
You may also be interested in...
Cracking Open the IPO Window for Pre-Commercial Device Companies
DexCom's is a bellwether IPO: if it holds its value, it could open the door for other pre-commercial device businesses. If it doesn't, it could keep it shut-as it's been since the class of 1995-96 device companies disappointed investors by missing their commercial targets.
Cracking Open the IPO Window for Pre-Commercial Device Companies
DexCom's is a bellwether IPO: if it holds its value, it could open the door for other pre-commercial device businesses. If it doesn't, it could keep it shut-as it's been since the class of 1995-96 device companies disappointed investors by missing their commercial targets.
Cracking Open the IPO Window for Pre-Commercial Device Companies
DexCom's is a bellwether IPO: if it holds its value, it could open the door for other pre-commercial device businesses. If it doesn't, it could keep it shut-as it's been since the class of 1995-96 device companies disappointed investors by missing their commercial targets.